In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC & PBMs: So What?

Executive Summary

The FTC's August announcement of its settlement agreement with Merck/Medco Managed care outlined rules governing the PBM's relationaship with Merck & Co. Inc. The FTC's aggressive tone--which suggested that Medco acknowledged that past actions in promoting Merck drugs restricted competition and resulted in higher prices for some drugs--made the agreement seem like a victory for the FTC and upset Medco officials who concede no such things.

You may also be interested in...

Pink Sheet Podcast: Fall Vaccine Adcom, COVID-19 Vaccine Price Trend, Plasma DTC Ad Questions

Pink Sheet reporters and editors dig into the emerging coronavirus vaccine regulatory schedule, look at vaccine purchasing trends, and consider the curious case of a federal government billboard encouraging convalescent plasma donations.

Industry Impact: Siemens Healthineers $16.4Bn Acquisition Of Varian – What Next?

Siemens Healthineers' acquisition of radiation oncology company Varian Medical Systems creates an oncology giant. Analysts disagree on whether its the right move for the companies.

Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus

Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts